Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

A cancer drug that was approved in the US just last week for pancreatic cancer is also showing promise in lung cancer treatment.

The drug, daraxonrasib (Rasonque), showed encouraging results in patients with previously treated RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 clinical trial led by researchers at The University of Texas MD Anderson Cancer Center. The results were published in the New England Journal of Medicine on September 2.

Rasonque is not approved for lung cancer yet. The new findings are early-stage evidence, and a larger Phase 3 trial is now underway.

More About This Drug

Pancreatic cancer is considered one of the most RAS-driven cancers, with more than 90% of patients carrying tumours driven by RAS protein mutations.

RAS mutations are found in about 30% of non-small cell lung cancers, making them among the most common cancer-driving alterations in the disease. Yet, apart from treatments targeting the specific KRAS G12C mutation, patients with other RAS mutations have had few treatment options.

Also read: Daraxonrasib: US FDA Approves Once-Daily Pill for Metastatic Pancreatic Cancer

What Did The Lung Cancer Trial Find?

The most relevant results came from 38 patients with NSCLC who received doses of 160 to 220 mg. These patients had already been treated with chemotherapy and immunotherapy but had not received docetaxel.

The tumours shrank in about 42% of patients. The duration of response was 11.5 months, while progression-free survival was 8.3 months and overall survival was 16 months.

For comparison, earlier studies of docetaxel in this treatment setting have reported response rates of around 9% to 14%, with progression-free survival of roughly 3 to 4.5 months.

As these results come from a small, early-stage study and are not a comparison with docetaxel, they need to be interpreted further cautiously.

Also read: Blocked Ears After Flight Turned Out To Be Rare Head And Neck Cancer In 22-Year-Old

Researchers React

David Hong, M.D., deputy chair of Investigational Cancer Therapeutics at MD Anderson and the study's lead investigator, said, “Immunotherapy has improved outcomes for many patients with non-small cell lung cancer, but the majority of these cancers eventually progress.”

“At that point, the few treatment options available to these patients often have modest clinical benefit and substantial toxicities, so these early results are encouraging.”

The drug did cause side effects. At the Phase 3-selected dose, 51% of patients experienced a grade 3 or higher adverse event, while 71% required dose modifications and 10% discontinued treatment. Rash was particularly common, affecting 90% of patients, while diarrhoea, nausea and vomiting were also reported.

Hong noted that “the toxicities are largely manageable compared to the alternatives available.”

The Drug Is Already Approved For Pancreatic Cancer

The interesting development comes shortly after the US FDA approved Rasonque on August 26, 2026. It is first targeted therapy in this new class for metastatic pancreatic adenocarcinoma.

In a 500-patient pancreatic cancer trial, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy. Similar RAS-targeting drugs are now being developed by other companies for pancreatic, lung and colon cancers.

The Pentagon has implemented a new policy requiring US service members aged 30 and older to undergo annual testosterone screening. The hormone is often associated with ageing, muscle and sexual health.

The policy, announced by US Defense Secretary Pete Hegseth in July, is meant to identify testosterone deficiency and assess whether it could affect the health and performance of service members. The latest Pentagon guidance means the screening is now set to begin immediately.

But being over 30 automatically does not mean you need to get your testosterone levels checked. Medical guidelines generally distinguish between simply having a low testosterone reading and having clinically significant testosterone deficiency.

What Is Low Testosterone?

Testosterone levels naturally change with age, but a lower reading does not automatically mean a person has a hormone disorder.

The Endocrine Society recommends diagnosing hypogonadism only when a man has symptoms or signs consistent with testosterone deficiency as well as consistently low testosterone levels. It also recommends confirming a low result with a repeat morning fasting testosterone test.

Also read: GLP-1 Drug Semaglutide Extends Lifespan In Healthy Older Mice By 12%, Study Finds

What Are The Symptoms Of Low Testosterone?

Possible symptoms of low testosterone include:

• Reduced sex drive
• Erectile dysfunction or fewer spontaneous erections
• Reduced energy
• Lower sperm count or infertility
• Loss of muscle mass
• Breast enlargement or tenderness
• Changes in mood or concentration

Poor sleep, obesity, stress, medications and other medical conditions can also contribute to fatigue, low libido or changes in physical performance. That is why a blood test alone should not be used to diagnose the condition.

Also read: Stroke Damage May Continue Even After The Clot Is Gone: Research Reveals Why Some Patients Fare Worse

Everyone Over 30 Does Not Need A Testosterone Test

This is where the Pentagon's approach differs from conventional clinical practice. The Endocrine Society's guideline recommends against routine screening of men in the general population for hypogonadism. Instead, testing is generally considered when symptoms and clinical circumstances suggest testosterone deficiency.

That distinction has sparked questions from doctors about the evidence behind universal screening of military personnel aged 30 and above.

According to Reuters, four of six doctors consulted questioned whether there was strong evidence that testing every service member in this age group would improve combat readiness.

Also read: Nearly 8 In 10 US Young Adults Show Signs Of Heart, Kidney Risk: Why Early Checks Matter

How To Treat Low Testosterone?

The Endocrine Society also recommends evaluating the underlying cause of low testosterone before treatment. That is important because testosterone levels can sometimes be affected by an underlying illness or other reversible factors.

The symptoms, repeated hormone measurements and the reason behind the low level of testosterone play a key role in deciding whether someone actually has testosterone deficiency and needs treatment.

While the GLP-1 drug semaglutide (marketed under the brand names Ozempic and Wegovy) has established its benefits in treating diabetes, supporting weight loss and improving heart health, a new study has found that it may also have the potential to extend lifespan in older, healthy mice — by 12%.

GLP-1 drugs have previously been found to delay the onset of several age-related diseases in animals. However, the new study, published in Nature, provides evidence in healthy older mice that these drugs may slow physiological aging itself.

“Most chronic diseases are deeply rooted in the aging process. If GLP-1 agonists do indeed slow it down, then a wide range of clinical benefits is exactly what you’d expect to see,” said Rafael de Cabo, a senior investigator at the NIH’s National Institute on Aging (NIA).

How Did Semaglutide Extend Lifespan In Healthy Mice?

The NIH-funded study found that semaglutide extended lifespan in older, healthy mice by tempering some of the detrimental effects of aging.

Researchers at the University of California, Berkeley, directly compared the effects of semaglutide with those of reduced food intake.

They found that the drug mimicked some of the anti-aging benefits of calorie restriction, while providing greater benefits in some areas.

To understand the impact of GLP-1 treatment at a time when the effects of aging are most pronounced, the study authors, led by Danica Chen, administered semaglutide to 20-month-old female mice for three months.

Also read: Can Ozempic-Like GLP-1 Drugs Slow Aging, Boost Longevity?

Compared with a control group, mice treated with the drug showed improved muscle and cognitive function. Gene expression analysis also showed that several hallmarks of natural aging, including increased inflammation and reduced regenerative capacity, were reduced in the treated animals.

Animals treated with the GLP-1 drug semaglutide, had a median lifespan of 834 days — 12% longer than mice in the control group, which lived for a median of 742 days.

Semaglutide Vs Calorie Restriction

Another group of mice was treated with semaglutide until the end of life and were compared with calorie restriction to determine whether the drug’s benefits were simply due to reduced food intake or involved other effects.

Over five months, scientists administered semaglutide to one group of 20-month-old female mice, while another group received a 24% calorie-restricted diet that matched the treated animals’ feeding pattern.

The researchers found that semaglutide-treated mice showed improvements in activity, spatial memory and blood-sugar control.

The groups also differed in metabolic rate. It was reduced in the calorie-restricted animals but remained largely unchanged in the semaglutide-treated mice.

“These differences point to the possibility that GLP-1 drugs tap into a biological pathway independent of calorie restriction. Uncovering this potential route and the benefits that may specifically stem from it is an important direction for future research into the development of longevity-enhancing interventions,” said Chen, corresponding author of the study and professor of metabolic biology and nutrition at UC Berkeley.

Read More: GLP-1 Weight Loss Drugs Ozempic, Wegovy, Mounjaro Tied To Over 60 Reported Deaths In Australia

What Does This Mean For Humans?

While these findings may guide future research, they do not mean that similar results can immediately be expected in humans.

Additional clinical studies will be needed to determine whether GLP-1 drugs can improve longevity in human patients.

Future clinical investigations may also explore potential benefits in healthy older adults, Chen explained, which could broaden the application of GLP-1 drugs.